Alzheimer's drug Leqembi may help over 75% people remain stable or improve

• A real-world study found that most patients receiving the anti-amyloid therapy Leqembi (lecanemab) remained clinically stable after 17 months, with 75.9% remaining at the same stage and 6.6% improving by 1 disease stage, for an overall 82.5% stable or improved.
• Clinical stability was reported regardless of sex, race, ethnicity, or APOE e4 genetic status, suggesting consistent real-world effectiveness across a diverse patient population.
• Nearly 87% of participants continued Leqembi treatment, indicating that most patients remained on therapy in routine clinical practice.
• Safety was consistent with previous studies, with adverse events occurring in 12.3% of people, with most cases reported as mild and asymptomatic, aligning with the drug’s established safety profile from clinical trials.

At present, there is no cure for Alzheimer’s disease. Current treatment approaches include lifestyle changes, therapies, and medications, which may slow the progression of the condition and manage its symptoms.

Some medications, known as anti-amyloid therapy, aim to reduce the buildup of beta-amyloid plaques in the brain, a hallmark of the disease. However, recent research has questioned the effectiveness of these medications.

While receiving treatment for Alzheimer’s, maintaining clinical stability is an important goal. It can allow an individual to preserve cognitive function, independence, and quality of life for as long as possible.

Now, a real-world study, presented at the Alzheimer’s Association International Conference (AAIC) 2026, noted that more than three-quarters of people with early Alzheimer’s disease who received the anti-amyloid therapy Leqembi (lecanemab) remained at the same stage of disease after an average of 17 months of treatment.

The data were presented at AAIC 2026 but has not yet undergone peer review or been published in a scientific journal.